With two children to care for the patient would benefit from being able to return home as quickly as possible.
- 54% of patients in the single dose study were treated as out-patients10.
- Dalbavancin does not require weight-based dose adjustment1,10.
- In DISCOVER 1 & 2, 12% of the patients were diabetic8.
- In Phase 2 & 3 trials 71% had a BMI >2510.
Single-dose dalbavancin is an effective treatment option for outpatients with ABSSSI and is associated with a high degree of patient treatment satisfaction and convenience.